Skip to main content
News Icon

Europe is a top destination for many researchers

ImmunoSensation2 Scientist, Dr. Bernardo Franklin was feature in a Nature article entitled "Europe is a top destination for many researchers". The article interviewed scientists from different parts of the world who are working in the EU.

“Science is not a recognized profession in Brazil, where I come from,” says Bernardo Franklin, an immunologist at the University of Bonn in Germany. “In Germany, PhD students are given working contracts, with regulations that provide them with insurances, pension and other benefits, and protect them from exploitation and abusive supervisors.”

Publication

https://www.nature.com/articles/d41586-019-01570-3

Related news

News Icon

Publication

Malaria Causes Permanent Damage to Phagocytes in the Spleen

—Macrophages formed in the bone marrow can only assume the function of embryonal phagocytes, or “scavenger cells,” to a certain degree according to a study by the University of Bonn and the Peter Doherty Institute for Infection and Immunity at the University of Melbourne. The researchers have demonstrated that malaria infection causes permanent damage to resident CD163 macrophages in the spleen, which are responsible for cleaning the blood, recycling iron and communicating with other cells involved in the body’s immune response.
View entry
Tracking glioblastoma cell spread in human brain tissue

Publication

Core2Edge: How tumor cells conquer the brain

—Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs. Bonn researchers have now developed Core2Edge, a model based entirely on human tissue that captures these hard-to-access infiltration zones at the tumor margin. The model enables investigation of the invasive front and direct assessment of new drug candidates in human tissue - without the need for animal testing. The study of the Brain Tumor Translational Research Group has now been published in Nature Protocols.
View entry
Mikrochip zur Wiederherstellung zentralen Sehvermögens bei fortgeschrittener Makuladegeneration.

Publication

Approval of a Novel Retinal Implant Technology

—A novel retinal implant is offering people with geographic atrophy the opportunity to regain part of their central vision for the first time. Geographic atrophy is a severe late stage of age-related macular degeneration. An international research team led by Prof. Frank G. Holz of the UKB and the University of Bonn demonstrated in an international clinical trial that the majority of participants experienced significant improvements in visual acuity. The novel retinal implant technology has now received approval for routine clinical use in Europe, making it available beyond clinical trials.
View entry

Back to the news overview